Sionna Therapeutics, Inc. (SION)
NASDAQ: SION · Real-Time Price · USD
3.810
-0.060 (-1.55%)
Oct 28, 2026, 9:30 AM EDT - Market open
Sionna Therapeutics Stock Forecast
SION's stock price has decreased by -90.13% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 12 analysts polled by S&P Global, Sionna Therapeutics stock has a consensus rating of "Hold" and an average price target of $21. The average 1-year stock price forecast is 451.18% higher than the current stock price, while the lowest is $5.00 (+31.23%) and the highest is $63 (+1,553.54%).
Price Target: $21 (+451.18%)
Analyst Consensus: Hold
Price Target
Chart* Price targets were last updated on Sep 19, 2026.
Analyst Ratings
The average analyst rating for Sionna Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 8 | 1 | 2 | 2 |
| Buy | 1 | 1 | 1 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 10 | 10 | 10 |
| Sell | 1 | 1 | 1 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 11 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| LifeSci Capital | LifeSci Capital | Hold Maintains $6 | Hold | Maintains | $6 | +57.48% | Sep 19, 2026 |
| Guggenheim | Guggenheim | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Sep 16, 2026 |
| Wedbush | Wedbush | Hold Maintains $5 → $6 | Hold | Maintains | $5 → $6 | +57.48% | Sep 15, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Hold Maintains $7 | Hold | Maintains | $7 | +83.73% | Sep 15, 2026 |
| Freedom Capital Markets | Freedom Capital Markets | Hold Maintains $38 → $5 | Hold | Maintains | $38 → $5 | +31.23% | Aug 11, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.45
from -1.88
EPS Next Year
-2.23
from -2.45
EPS and Forward PE are based on non-GAAP adjusted numbers.